Login / Signup

Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.

Upendra Rao AnumalaJo WaalerYves NkizinkikoAlexander IgnatevKatina LazarowPeter LindemannPetter Angell OlsenSudarshan MurthyEzeogo ObajiAlexander G MajougaSergey LeonovJens Peter von KriesLari LehtiöStefan KraussMarc Nazare
Published in: Journal of medicinal chemistry (2017)
A structure-guided hybridization approach using two privileged substructures gave instant access to a new series of tankyrase inhibitors. The identified inhibitor 16 displays high target affinity on tankyrase 1 and 2 with biochemical and cellular IC50 values of 29 nM, 6.3 nM and 19 nM, respectively, and high selectivity toward other poly (ADP-ribose) polymerase enzymes. The identified inhibitor shows a favorable in vitro ADME profile as well as good oral bioavailability in mice, rats, and dogs. Critical for the approach was the utilization of an appropriate linker between 1,2,4-triazole and benzimidazolone moieties, whereby a cyclobutyl linker displayed superior affinity compared to a cyclohexane and phenyl linker.
Keyphrases
  • photodynamic therapy
  • single molecule
  • small molecule
  • molecular docking
  • high throughput
  • type diabetes
  • structural basis
  • high fat diet induced
  • label free
  • adipose tissue
  • insulin resistance